Triangulum offers CRO services with extensive expertise in conducting preclinical efficacy, proof-of-concept and mechanism of action studies in various animal models of type 2 diabetes. Our scientists have outstanding track record of working with ob/ob, db/db, DIO-Streptozotocin, DIO mice as well as Zucker Diabetic Fatty (ZDF) rats and DIO-Streptozotocin rats. Our team has the skills and experience needed to evaluate your preclinical drug candidates such as small molecules, biologics and RNA therapeutics in acute and chronic efficacy studies. We provide hyperinsulinemic-euglycemic clamp studies, OGTT, IPGTT, ITT and histopathology services. Our scientists provide professional interpretation of the preclinical efficacy data to accelerate your drug development.